Business Wire

FEATURESPACE

16.8.2022 16:02:11 CEST | Business Wire | Press release

Share
Featurespace and Vital4 Partner to Provide Enhanced Watchlist Screening

Featurespace and Vital4 have signed a global partnership to provide the financial services industry with AI driven Watchlist, PEPs, Sanctions and Adverse Media screening through Featurespace’s award winning ARIC Risk Hub. With this partnership, ARIC Risk Hub for AML is a one stop, end-to-end financial crime prevention solution for the customer.

Through a single API, ARIC Risk Hub for AML will leverage the watchlist data collected and curated by Vital4 to enhance the performance of Featurespace’s self learning models, ultimately improving accuracy and reducing false positives in flagged entities and transactions. Vital4’s automated AML/ KYC data tools analyze more than 6,000 global watchlists to help identify subjects involved in sanctions, terrorism, or corruption.

“Given the complementary technologies of Featurespace and Vital4, the industry now has access to behavioral analytics coupled with sentiment analysis to truly identify the financial criminals in real time.” Said Dave Excell, Featurespace Founder.

Vital4’s AI driven system examines 13 important criteria to provide the highest levels of name-matching, removing the ambiguity of legacy systems that rely on fuzzy name matching that can miss critical data points.

“As financial crime becomes increasingly complex to combat, crossing borders and moving in real-time, AML professionals need a complete risk hub to effectively monitor and report suspicious transactions and remain compliant.” Said Amy Barbieri, Co-Founder and President of Vital4. “The risk of non-compliance has huge reputational impact, making the business case clear for technologies that improve the accuracy for anti-financial crime efforts”.

Featurespace and Vital4 are two Atlanta based AI driven technology companies led by industry leading women. The two companies are unified around a shared commitment to enable banks and financial instutions with the best technology to fight financial crime and make the world a safer place to transact.

Primary industry benefits:

AI Driven Watchlist Screening :

  • Machine learning to manage increasing volume and variety of transactions and entities to screen and monitor
  • Monitoring over 6,300 Watchlists and Global Sanctions in 200+ countries and regions
  • Propriety entity and name matching to provide more accurate search results and reduce false positives
  • Proprietary 13-point name matching algorithm – better than traditional fuzzy name matching logic
  • Natural Language Processing and Sentiment Analysis to truly identify Adverse Media articles AI-powered tagging of individuals or businesses in articles
  • Watchlists updated real-time
  • Risk-based call-out depending on business rule logic, analytics output

Customer Screening

  • Screening at onboarding, change of details and ongoing trigger-based or scheduled monitoring
  • Risk-based screening policies determine depth of search
  • Watchlist flags available for analysts and immediate use within rules

Real-time Transaction Screening

  • Real-time enabled sanctions screening of specified transaction types (i.e. cross-border, wires, ACH)
  • Screening of counterparties
  • Instant responses and action tags
  • Reviewed in context of wider account activity a single, intuitive UI

Featurespace continues to partner with best in class technologies to provide holistic FRAML solutions for smart thinking financial institutions. Featurespace's partnership with Vital4 provides customers with a consolidated view and ability to manage financial crime risks across AML, fraud and sanctions within a single next generation risk management platform. Featurespace’s partnership with Callsign provides Enhanced Authentication and Device ID and security is provided by Accertify, and Ciphertrace provides crypto intelligence for transactional monitoring.

About Featurespace

Featurespace is the world leader in enterprise grade technology that prevents fraud and fights financial crime. With a mission to make the world a safer place to transact, Featurespace helps banks and financial institutions protect consumers, and reduce risk and operating costs by providing industry-leading machine learning, financial crime prevention solutions. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks and is the first to profile both genuine and fraudulent behavior to identify and catch criminal activity in real time. Both are patent pending technologies that are central to Featurespace’s award winning ARIC™ Risk Hub. Over 70 direct customers and 100,000 merchants and financial institutions have put their trust in Featurespace’s technology including HSBC, NatWest, TSYS, Worldpay, Marqeta, Contis, Danske Bank, Akbank, Edenred and Permanent TSB. Founded in 2008, and headquartered in Cambridge, UK Featurespace has a team of over 400, operating globally from seven locations.

About Vital4

Vital4 is an award-winning global technology company that provides critical data to organizations for regulatory compliance and to help mitigate third-party risk. Striving to make the world a safer place, Vital4 helps identify illicit actors in the fight against financial crime, terrorism, fraud, and corruption. Vital4 was founded with four fundamental concepts in mind: compliance, accuracy, global insight, and value. The powerful search platform, Vital4Search, was built with a “tech first” approach anchored by AI and Machine learning and is the world’s fastest and most accurate proprietary data search technology on the market today. Vital4Search solves enterprise compliance problems by eliminating slow update cycles, shallow source pools and reducing the human error risk of manual legacy processes. Vital4 provides data solutions to thousands of users in banking, gaming, identity, gig economy, GRC, legal, insurance and 4 of the top 5 largest background screening companies in the world put their trust in Vital4.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye